Previous 10 | Next 10 |
Dicerna Pharmaceuticals ( DRNA ) is a clinical-stage company with RNAi-based therapies in development for multiple diseases. Its most advanced therapy is DCR-PHX for Primary Hyperoxaluria, which is currently in a Phase 1 trial. To be approved for commercial use by the FDA it would need to pass...
Dicerna Pharmaceuticals (NASDAQ: DRNA ) has submitted a Clinical Trial Authorization application to the Swedish Medical Products Agency to conduct a first-in-human Phase 1/2 study of DCR-A1AT, an investigational therapy from GalXC technology platform, for the treatment of alpha-1...
— Company Submitted Clinical Trial Application and Plans to Initiate Multicenter Phase 1/2 Trial in Third Quarter of 2019 — — Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Program Broadens Dicerna’s Commitment to Addressing Chronic Liver Diseases...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant o...
Dicerna Pharmaceuticals (NASDAQ: DRNA ) announces updated data from its ongoing PHYOX1 Phase 1 trial evaluating DCR-PHXC, a GalXC product candidate. More news on: Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
—Researchers Report Substantial Oxalate Reduction Following Single-Dose Administration of DCR-PHXC in Additional Patients with PH2— —Enrollment Underway in Pivotal PHYOX2 Trial of DCR-PHXC— Dicerna TM Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “...
– Prof. Bernd Hoppe, M.D., Appointed Vice President, Global Medical Affairs at Dicerna – Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (...
— Steven Kates, Ph.D., Joins Company as Vice President, Regulatory Affairs — — David Caponera Appointed Head of Patient Advocacy and Patient Services — Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicer...
— Company Expands Management Team and Bolsters Commercial Capabilities to Support Continued Growth — Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, ...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...